


## XR8-89

<b>Cat. No.:</b>	HY-150784
<b>CAS No.:</b>	2817811-16-6
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>36</sub> N <sub>4</sub> O <sub>2</sub> S
<b>Molecular Weight:</b>	504.69
<b>Target:</b>	SARS-CoV
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (99.07 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.9814 mL	9.9071 mL	19.8141 mL
5 mM	0.3963 mL	1.9814 mL	3.9628 mL
10 mM	0.1981 mL	0.9907 mL	1.9814 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

XR8-89 is a potent papain-like protease (PL<sup>Pro</sup>) inhibitor with an IC<sub>50</sub> value of 0.1 μM. XR8-89 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. XR8-89 can be used for SARS-CoV-2 research [1].

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 0.1 μM (papain-like protease)<sup>[1]</sup>

#### In Vitro

XR8-89 induces conformational changes mainly in BL2 region and increases the activity against PL<sup>Pro</sup>[1].  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Ferreira GM, et, al. Inhibitor induced conformational changes in SARS-COV-2 papain-like protease. Sci Rep. 2022 Jul 8;12(1):11585.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA